Epic AI Scribe: Workflow, Privacy, Pricing, and Evidence (2026)

Epic AI scribe can mean two different things: Epic’s built-in ambient charting or a third-party scribe connected to Epic. The distinction changes who supplies the software, which workflow your organization enables, and which contracts and support teams you need. Start there before comparing note quality or price.

Epic announced the release of AI Charting in February 2026; more recent material calls its native ambient capability Chart with Art. This guide focuses on choosing and evaluating an Epic documentation route: capture, draft notes, proposed orders, clinical review and the final encounter record. For a broader introduction to recording boundaries and speaker errors, use our ambient scribe guide.

Public-evidence assessment · Sources checked September 16, 2026. Vero sells competing AI documentation software. Epic did not sponsor or review this article. Jordan Reeves is a Vero contributor; no hands-on Epic session or separate clinician/privacy-specialist review has been completed. Published product claims and proposed tests are identified separately. This is purchasing and workflow information, not patient-specific medical or legal advice. See our editorial policy.

What Epic offers in 2026

Epic’s February 4 release announcement describes listening during visits, drafting clinician notes and queuing orders from the conversation. It also describes voice-driven adjustments to note structure. These are vendor-described capabilities, not findings from our own session.

The current Art product page, checked September 16, describes both outpatient and inpatient/ED drafting. Art is the broader offering; ambient charting is one part of it. The following scope map separates published capabilities from local availability.

Keep release, local deployment and an expanded pilot separate. In its August 18 report on Ochsner’s Ergo Visit pilot, Epic describes a wider visit experience combining chart context and documentation. Four family/internal medicine clinicians began the pilot on August 3 after an accelerated system upgrade. That is a specific early deployment—not proof that every Epic customer has the same experience enabled.

For your organization, request the exact product name, production release, enabled departments, encounter types, languages, capture devices and support owner. Mark a capability “available locally” only after the application team confirms it. A feature appearing in a presentation or a different hospital’s announcement is not enough.

Compare native, connected and standalone routes

The first two routes below have Epic documentation behind them. The third is a general workflow alternative, not an assertion that a particular standalone product has an Epic connection. Read across each row; these are not ranked products.

On smaller screens, swipe within the table or focus it and use the arrow keys.

The partner workflow comes from Epic Showroom’s Ambient Voice Recognition category, checked September 16. It describes a category-level pathway, not a guarantee about an individual implementation. Ask a shortlisted supplier to demonstrate your exact encounter and destination.

Open@Epic’s developer resources, checked September 16, explain that customers operate their own instances and decide which applications connect. There is no single central endpoint that grants access to all Epic patient records. Sandbox access and API documentation do not establish local production authorization. Our EHR integration guide covers the associated mapping, access and cutover questions.

An actionable comparison therefore names three owners: the application team enabling the workflow, the clinician accepting the record, and the commercial/privacy owner approving the supplier. If each believes another team owns a failed handoff, the purchase is not ready for launch.

Three named Epic-connected alternatives

These examples have product-specific public documentation, checked September 16, 2026. They are not a ranking or an exhaustive list. “Documented” does not mean enabled in your Epic instance, and an integration listing is not an endorsement or a product-performance audit.

For Abridge, compare its current product description with its December 18, 2025 order-suggestion update. For Dragon Copilot, read Microsoft's integrated-order requirements and Chat prompt boundaries. The Chat restriction is specific to that function, not proof that every integration has zero chart inputs. Nabla's current-versus-roadmap distinction comes from the linked Epic integration page.

Use these differences to shortlist by task. If prior-chart context is essential, request the actual read fields and a provenance example. If orders matter, require a demonstration from suggestion through authorized catalog entry. If note handoff is the main need, test the destination sections and subsequent edits. Do not give an unavailable roadmap feature the same score as a working local configuration.

Map the Epic scribe workflow

This is Vero’s proposed evaluation map, not an observed deployment. Its purpose is to expose separate control points that a polished end-to-end demonstration can hide.

1. 1. Confirm the encounter. Verify the test patient, visit, clinician role, template and enabled service before starting.
2. 2. Explain and start capture. Apply the approved patient-choice process. Check the actual capture indicator and all intended audio participants.
3. 3. Generate the draft. Establish when generation starts, whether the encounter remains active, and which chart context is used.
4. 4. Review the note. Check speaker attribution, negation, time, laterality, unsupported facts and the destination note type.
5. 5. Review proposed orders separately. Distinguish a discussion, a suggestion, a queued item and an authorized order. Verify every required field and disposition.
6. 6. Finalize and reconcile. Confirm the correct signed record and order states. Resolve duplicates, failed saves and incomplete sessions through a named recovery route.

What the native Epic evidence actually shows

Epic's Ochsner report gives the native sequence more detail: Art provides chart summaries linked to source notes before a visit; Chart with Art surfaces relevant chart information during the conversation; documentation and proposed orders are prepared for review. Those are documented features of the reported Ergo Visit pilot, not observed steps in our environment.

During a local demonstration, ask the operator to stop before signing. Inspect the draft note and proposed orders as different outputs. Then inspect the final encounter after authorization. A note that says a follow-up was ordered is not evidence that an order exists, and a queued order is not evidence that it was signed.

For telehealth, write down how the remote patient's audio reaches the capture service. A microphone hearing the clinician does not establish that it hears the remote speaker. For interpreter visits, identify patient, interpreter and clinician explicitly, rehearse interruptions, and inspect whether translated statements are assigned to the correct person. Use a language-qualified reviewer for language accuracy; the mere presence of three voices is only an audio-path test.

Epic AI scribe pricing and total cost

No public AI Charting price was found in the Epic release and product sources reviewed on September 16, 2026. Obtain an organization-specific licensing and deployment quote. Do not assume that it is free, bundled into every Epic agreement, or priced like a different ambient-scribe product.

Use the following quote schedule for native and connected options. A blank answer should remain unresolved rather than becoming a zero in the budget.

A transparent capacity calculation

Consider an illustrative clinic, not a measured Epic result: 10 clinicians each complete 160 eligible encounters per month. If a pilot eventually demonstrates a net reduction of 3 active documentation minutes per encounter, the calculation is 10 × 160 × 3 ÷ 60 = 80 clinician hours per month. At an assumed USD $100 per hour, that is USD $8,000 of time valued—not automatically cash saved or additional revenue.

Subtract subscription, amortized setup, support and any additional staff workload to compare economic value. Do not subtract review twice: the 3-minute assumption must already be net of clinician review, transfer and recovery. If the net reduction is zero, the time-based benefit in this example is zero, even if the generated draft appears quickly.

For year-one cash planning, use 12 × monthly committed fees + implementation fees + paid training/support + other incremental expenses. Keep salaried capacity value in a separate column. This prevents a proposal from describing recovered time as a cash saving without identifying an actual expenditure reduction. The digital scribe pilot guide provides a broader measurement worksheet.

Privacy questions to resolve before capture

“Inside the EHR” describes an interface location, not the complete processing chain. Request the service-specific data-flow diagram, applicable agreements, subprocessors, processing regions, access controls and retention schedule for the configuration being purchased.

For example, GHC-SCW’s February 2, 2026 deployment statement says recordings are stored for a limited period and are not used to train AI models. It also describes patient consent and clinician review. That is a named organization’s public statement. It does not give an exact retention duration or establish every customer’s contract, all derived-data uses, or every connected vendor’s practices.

For U.S. HIPAA-regulated organizations, HHS OCR’s cloud guidance, checked September 16, addresses appropriate business associate agreements and risk analysis for cloud services handling electronic PHI. Encryption alone does not remove these responsibilities. A vendor description should support—not replace—the organization's review of the actual service.

For Ontario physicians, CPSO’s AI guidance, checked September 16, addresses informing patients and obtaining consent before recording. Apply the requirements relevant to the location and profession; do not treat HIPAA or one Canadian college's guidance as a universal rule.

A patient explanation should identify what listens, what is produced, who reviews it, the verified handling of the recording and the alternative if the patient declines. Staff should know how to stop capture and return to the approved non-recording workflow. Avoid promising immediate deletion or “nothing leaves Epic” unless the specific service evidence supports that wording.

What the evidence can and cannot tell you

The sources below answer different questions. A deployment report can establish that a workflow is being used; it does not have the same design as a randomized comparison. Research on another product can inform a pilot without proving native Epic performance.

The Lukac trial: results by arm

The published trial randomized 238 outpatient physicians across 14 specialties. These were DAX Copilot and Nabla—not native Chart with Art. The full paper's model estimates compare baseline with month two after a month of familiarization; the times below are not raw medians.

This was an eight-week, single-institution study of English-language encounters. Uptake was 33.5% of DAX visits and 29.5% of Nabla visits. Epic Signal excluded editing inside vendor platforms, potentially overstating savings. Different interfaces and incomplete uptake limit interpretation. Separate comparisons with control do not establish significant DAX-versus-Nabla superiority or total-workflow time savings.

The practical inference is to measure the whole accepted-record workflow locally. Capture the time to review, correct, reconcile orders and recover failed sessions, not just the time until a draft appears. Preserve the numerator, denominator and exclusion rules. A report on only successful sessions cannot tell a buyer the workload created by failures.

Run six synthetic acceptance tests

Protocol EPIC-SCRIBE v1.0 · Prepared September 16, 2026 · Execution status: not run. These original Vero scripts are a proposed initial acceptance screen, not a validated instrument or a completed product test. Use an authorized non-production environment with synthetic records. The scripts are documentation-control exercises, not instructions for patient care.

Record the product/supplier, Epic and connected-app versions where available, template, role, encounter type, device, operating system, capture route, date and configuration. Run each case twice: once in a quiet room and once with a second staff speaker and a recorded description of the changed audio conditions. That is six cases × two runs = 12 scripted runs, not a clinical validation sample. Keep the script unchanged between repetitions; repeat on other required devices separately.

Use the exact wording below and retain the original generated output before correction. If the application lacks a required control, record “unsupported” and assess an approved alternative—do not improvise a production workaround. Capture state, permissions and draft behavior remain not tested in this article.

E-01: speaker attribution and a corrected timeline

Roles and script: caregiver: “I have had a cough for three days.” Patient: “I do not have a cough. My right wrist started hurting three days ago—sorry, two days ago.” Clinician: “The wrist concern belongs to the patient. The cough belongs to the caregiver.”

Expected facts: patient reports right wrist pain beginning two days ago and denies cough; caregiver reports cough. Prohibited additions: patient cough, left wrist pain, a three-day wrist duration, an examination or diagnosis not spoken. Count incorrect attribution separately from a wrong time value; one error should not disappear because the rest of the note reads well.

E-02: current conversation versus old chart context

Setup: put only this context into the synthetic prior note: “At the previous visit, the patient reported left wrist pain.” Current script: patient: “The old left wrist problem has resolved. Today I am reporting right wrist pain.” Clinician: “Record the old problem as historical, not today's active left-sided complaint.”

Expected: historical left-sided and current right-sided concerns remain distinct. Prohibited: copying the old complaint into the current assessment as active, claiming bilateral symptoms, or adding examination findings. Record whether the product actually retrieved the seeded context; a correct output without retrieval is a narrower test result.

E-03: discussion is not an authorized order

Script: clinician: “We may consider a complete blood count at a later visit. Do not place an order today. No laboratory order is being made in this encounter.” Patient: “I understand that no test is ordered today.”

Expected: the note preserves the deferred decision; no active laboratory order is created. Inspect separately: any proposed item, queue entry and signed order. A suggestion that requires removal is a recorded correction, not the same outcome as an unauthorized signed order. Do not send a test order to a real laboratory.

E-04: capture pause and private speech

Script before the pause: clinician: “The follow-up call is planned for Friday.” Use the documented pause control in the test environment and verify its displayed state. While paused, say: “Red umbrella. This phrase is outside the recorded conversation.” Resume through the supported control and say: “The clinic will make the Friday call.”

Expected: the Friday plan and clinic ownership remain; the off-record phrase does not appear in captured content or generated outputs available for inspection. Prohibited: assuming that closing a window is equivalent to pausing. Save the displayed state and the inspected output; an absent phrase alone does not prove that no audio was retained elsewhere.

E-05: encounter switching and destination

Setup: create synthetic encounters DEMO-A and DEMO-B. In A, say: “This encounter's reference phrase is blue notebook.” Stop or finalize capture using the documented workflow. Attempt the permitted transition to B and say: “This encounter's reference phrase is green folder.”

Expected: each output stays with its intended encounter; no blue-notebook content enters B. Record any enforced switching restriction and what the operator must do next. Prohibited: treating a blocked switch as a failure without checking its intended safety purpose, or overriding a safeguard to complete the script.

E-06: connection loss and retry

Script: clinician: “The clinic will call Friday.” At that point, interrupt only the test device's connection through an approved test method. After recovery, follow the documented resume or retry process, then say: “The call is still planned for Friday.” Inspect the resulting encounter.

Expected: an identifiable incomplete or recovered session, one appropriate final record, and no duplicated clinical action. Prohibited: silently assuming missing audio was recovered or repeatedly generating duplicates. Log the exact interruption point, warnings, recovery steps, active staff minutes and unresolved content gaps.

Keep a usable evidence record

For each run, store: case/repetition, expected result, raw output reference, observed discrepancy, severity under the clinical team's definitions, correction minutes, final destination and decision owner. “Not tested,” “unsupported,” “failed” and “passed after correction” are different outcomes. Agree which defects block use before testing, rather than moving the threshold after seeing the results.

Capture three synthetic-only artifacts where the authorized environment permits screenshots: the capture state, the draft with proposed orders, and the final encounter with its actual order states. Record screenshot date and configuration. No current-interface screenshots or execution findings are supplied here because no authorized test session was available.

Example completed E-03 record — fictional

Product / execution date

Unassigned / not run. This record illustrates the evaluation format only.

Example observation

The draft preserves the deferred laboratory decision, but a CBC suggestion appears in the proposed-order queue. No signed order exists.

Correction

Remove the suggestion and verify the note and final order list. Illustrative active correction time: 45 seconds.

Classification

Unexpected proposed action; requires clinical-owner severity assessment. Not equivalent to an unauthorized signed order.

Decision

Hold the relevant workflow pending configuration review and a repeated test. Do not report this fictional record as an Epic defect or a measured product result.

Who should evaluate each route?

Native Chart with Art is a logical candidate for an Epic organization seeking a locally supported documentation workflow. Its documented connection between conversation, note and proposed orders is a reason to evaluate it, not a reason to skip testing. The tradeoff is dependence on the organization's enabled release, configuration and commercial agreement. A clinician cannot infer personal access from a public launch.

A connected third-party scribe is a logical candidate when a named supplier meets a requirement the organization wants to compare. Request evidence for the actual integration: source of capture, chart context, output destination, permitted writes and failure ownership. The extra supplier boundary may add contracting and support coordination; it does not by itself prove worse quality or privacy.

A standalone workflow may merit evaluation when the organization permits it and the handoff remains workable. Include review and transfer in the timing comparison. A fast draft loses practical value if staff must repeatedly fix formatting, find the correct encounter or reconcile missing actions. Conversely, native placement alone does not prove superior output.

Where Vero belongs in the comparison

Vero Scribe is another documentation option to assess against the same clinic requirements. Vero publishes this article and has a commercial interest in that comparison. This assessment does not establish that Vero is more accurate, cheaper, safer or natively integrated with Epic. Ask for current product and contract evidence, then apply the same synthetic cases and final-record checks to the proposed Vero workflow.

The best next step is a locally authorized, bounded evaluation, not a universal product ranking: identify the route, obtain the quote and handling terms, execute the synthetic tests, and have clinical, application and privacy owners decide on the specific configuration. Preserve that decision with its scope and date so a later product or model change can trigger a focused recheck.